lnu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Dose patterns among patients using low-dose buprenorphine patches.
Nordic Health Economics AB.ORCID iD: 0000-0002-0518-6196
Show others and affiliations
2013 (English)In: Pain medicine (Malden, Mass.), ISSN 1526-2375, E-ISSN 1526-4637, Vol. 14, no 9, 1374-80 p.Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: The objective of this study was to investigate the dose pattern of low-dose buprenorphine patches among patients in Swedish clinical practice. The clinical experts among the coauthors interpreted the results in relation to possible indications of development of tolerance and/or dependence/addiction.

DESIGN AND SETTING: This was a nationwide, observational study using data from the Swedish Prescribed Drug Register.

SUBJECTS: Individuals who were dispensed the low-dose buprenorphine patches continuously for more than 24 weeks during July 1, 2005 to February 28, 2011 were included.

METHODS: The dose pattern was analyzed as the change in dose over time for each patient: 1) the dose at baseline compared with each of the following 8-week intervals, and 2) the dose at baseline compared with the dose during the patients' last treatment period.

RESULTS: The majority of the patients were female (74%), and most were 75 years and older (69%). The median treatment duration was 260 days, and 4% and 1% of patients remained on continuous treatment for 2 and 3 years, respectively. The mean dose was 11 μg/h at baseline, and 15 μg/h during the patients' last treatment period. The average dose increased by 4 μg/h during the patients' entire treatment course.

CONCLUSIONS: The average dose increased by 4 μg/h during the patients' treatment course, which lasted on an average of 260 days. From a clinical perspective, the dose increase of 4 μg/h is low and does not suggest dependence/addiction, as also supported by the low proportion of patients remaining on continuous treatment.

Place, publisher, year, edition, pages
2013. Vol. 14, no 9, 1374-80 p.
National Category
Health Care Service and Management, Health Policy and Services and Health Economy
Identifiers
URN: urn:nbn:se:lnu:diva-29976DOI: 10.1111/pme.12142PubMedID: 23692014OAI: oai:DiVA.org:lnu-29976DiVA: diva2:659450
Available from: 2013-10-25 Created: 2013-10-25 Last updated: 2017-12-06Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Ericson, Lisa

Search in DiVA

By author/editor
Ericson, Lisa
In the same journal
Pain medicine (Malden, Mass.)
Health Care Service and Management, Health Policy and Services and Health Economy

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 62 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf